reported by youarewithinthenorms
NORMAN J CLEMENT , RPH, DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS MD, PH.D., DAVID STEIN, MD IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., LEROY BAYLOR, JAY K. JOSHI MD., MBA, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
Be aware that neither of the “studies” noted by Norman Clement included the term “magnificent hoax”, though I personally agree with the sentiment…
…The paper for the Medical Research Archives of the European Society of Medicine is new out this morning, having proceeded from a personal invitation by their section editor on pain management. The paper will also appear next month in a special edition of the Archives on “Challenges and Opportunities in Pain Management”. The second paper on “The Blind Leading the Blind” is still circulating in draft and will hopefully be published a different US journal after I have completed the writing this month..
…Richard Red Lawhern
THE LAWHERN STUDY
” The United States is currently embroiled in a contentious and multi-dimensional public conversation about addiction-related mortality, chronic pain, and government regulation of clinicians who employ opioid analgesic pain relievers in treating pain. The US Centers for Disease Control and Prevention (CDC) has published an updated guideline to clinicians concerning appropriate practices for managing severe chronic pain utilizing opioid analgesic pain relievers.
“Taken in combination, these factors may warrant the repudiation of both CDC-2016 and CDC-2022, and withdrawal of CDC from policy making roles in the practice of pain medicine.”
This Critical Policy Review briefly outlines US public health policy’s history of regulating prescription opioid pain relievers. The author then compares recommendations and data sources of the updated November 2022 CDC guidelines against findings from a wide range of pertinent clinical literature.
CDC OPIOID GUIDELINES: “A FATALLY FLAWED MAGNIFICENT HOAX“
He finds that the most recent effort by the CDC is fatally flawed by weak evidence and methodologically unsound research, disproportionate emphasis on risk, and failure to address genetically mediated variability in minimum effective opioid dose between individuals.
Compounding these difficulties are indications of professional conflicts of interest and persistent anti-opioid bias by authors of the most recently released CDC guidelines.”
THE TARGETING PACKAGES
DEA OWN ENFORCEMENT VIDEO DEMOSTRATES ITS METHODOLOGY BASED ON THE USE OF
FRAUDLENT DATA ANALYTICS COLLECTION AND CONCLUSIONS
THE MINORITY REPORT-THOUGHT CRIME-1984
This means there is no way to know whether misused drugs originate from theft of warehouses or trucks versus those prescribed by physicians. Indeed, the claim that “pill mills” are responsible for drug addiction, deaths, and morbidity is fake science.
As Anderton, the Precrime agency in the Tom Cruise movie “Minority Report,” Chief, David Abrams, Assitant Attorney General in New York State Office of The Attorney General, explains this procedure’s advantages. As he has adopted and shaped his reality from the Movie:
”In our society, we have no major crimes … but we do have a detention camp full of would-be criminals.” He cautions about the basic legal drawback to pre-crime methodology: “We’re taking in individuals who have broken no law.”
STUDY EXPOSES DAVID ABRAMS ASSITANT ATTORNEY GENERAL OF NEW YORK STATE OFFICE OF THE ATTORNEY GENERAL, METHODOLOGIES “IN HIS BELOW VIDEO,” AS COMPLETELY FRAUDULENT
The Government, through the National Benefit Integrity Medic (NBI MEDIC), engages in Pre-Crime, criminal forensics, data analytics, artificial intelligence, and computer programs, with titles like “Multi-Prescriber Vulnerability,” “Pill Mill Doctor” project, Trio Prescriber 1.0 and 2.0, Doctor Shopper Prescriber, Pill Mill Prescriber 2.0, Subsys Analysis, Death Analysis, Peer Comparison, Prescriber Schedule II Controlled Substances Risk Assessment 1.0, Pharmacist Clinical Reviews, Subsys Analysis, Death Analysis, Predictive Model Learning Analytics Tracking Outcome (PLATO) tool and Peer Comparison PLATO Profile.
LAWHERN STUDY DEBUNKING DOJ-DEA ENFORCEMENT FALSE NARRATIVE AND METHODOLOGIES
Richard Lawhern, Ph.D;
“Doctors Diagnosing Addiction — Are the Blind Leading the Blind?” My working hypotheses are as follows. I’ve developed this framework in part with the able input of Dr Stephen E Nadeau, with whom I have enjoyed a rich collaboration over more than five years:
- Clinical prescribing of opioids, particularly at high doses and for prolonged periods, predictably leads to physiological dependency, characterized solely by withdrawal symptoms and breakthrough pain when opioids are rapidly withdrawn. Dependency is an expected and acceptable side effect of treatment for severe pain that is otherwise intractable to non-opioid therapies. So-called “psychological” addiction in medical patients lacks a firm research basis.
- “Pseudo-addiction” is an outcome of clinician mis-training that imputes patient awareness of what works or doesn’t work in their own past medical history, with “drug seeking behavior”. It is entirely appropriate for patients to report what works to a clinician who is otherwise unfamiliar with their medical history. State PDMP records can help clinicians detect individuals who may be shamming pain to obtain prescriptions for resale. Repeated reports of lost or stolen prescriptions are also a substantive indicator.
- Dependency is not addiction, but few doctors are prepared by their training to recognize the differences. Likewise, research backing is very weak for what are called “psychosomatic” disorders, including “psychogenic” pain. Even if doctors actually had training in diagnosis of addiction, the DSM “standard” of diagnosis is so deeply flawed that the US National Institutes of Health have declared that the DSM-5 can no longer be used as an organizing framework for future research in behavioral health.
- Most medical doctors have no current training in the use of the APA Diagnostic and Statistical Manual (version IV or 5) or the International Classification of Diseases (ICD-10A) to determine and qualify diagnoses of “addiction”. They are therefore forced to fall back on their general impressions and biases, under the influence of the prevailing climate of public misinformation and DEA/State Medical Board persecution of doctors who treat pain with opioids.
- The aggregate result of these factors is that “addiction” or “substance use disorder” are likely very much over-reported in electronic health records employed in large-scale retrospective studies of the outcomes of medical prescribing.
- The incidence of actual substance use disorder as a result of clinically supervised opioid prescriptions is so low that we cannot reliably measure it within the confounding factors that exist in electronic health records. Effects of clinical prescribing get lost in the noise of illegal street drugs. Over-prescribing never was and isn’t now the source of our US “opioid crisis.”
QLARANT ALGORITHMS DEBUNKED!!!
Database-driven tracking has been linked to a decline in opioid prescriptions, but the evidence is mixed on its impact on curbing the epidemic. Overdose deaths continue to plague the country, and patients like Amirault have said the monitoring systems leave them feeling stigmatized as well as cut off from pain relief.
To manage the pain, many use prescription opioids, which are tracked in nearly every state through electronic databases known as prescription drug monitoring programs (PDMPs).
In this promotional video, the company said its algorithms can “analyze a wide variety of data sources,” including court records, insurance claims, drug monitoring data, property records, and incarceration data to flag providers.
However, William Mapp, of Qlarant the company’s chief technology officer, stressed the final decision about what to do with that information is left up to people — not the algorithms.
Mapp said that “Qlarant’s algorithms are considered proprietary and our intellectual property” and that they have not been independently peer-reviewed.
“We do know that there’s going to be some error percentage, and we try to let our customers know,” Mapp said. “It sucks when we get it WRONG!!!!
AMERICAN MEDICAL ASSOCIATION
“These unknown and unreviewed algorithms have resulted in physicians having their prescribing privileges immediately suspended without due process or review by a state licensing board — often harming patients in pain because of delays and denials of care,” said Bobby Mukkamala, chair of the AMA’s Substance Use and Pain Care Task Force.
Even critics of drug-tracking systems and algorithms say there is a place for data and artificial intelligence systems in reducing the harms of the opioid crisis. “It’s just a matter of making sure that the technology is working as intended.”
FOR NOW, YOU ARE WITHIN